Designation elevates site as a Syneos Health partner for best clinical research practices
Barcelona, July 30, 2020.- The Vall d’Hebron Institute of Oncology (VHIO), was recently named a Catalyst Site by Syneos Health (NASDAQ:SYNH), the only fully integrated biopharmaceutical solutions organization. Syneos Health’s Catalyst Program is designed to support faster start up and efficient delivery of studies for biopharmaceutical customers across a number of therapeutic areas including oncology.
VHIO was selected to participate in the invitation-only Syneos Health Oncology Site Network alongside other high-performing sites to drive continuous improvement and development of best practices in clinical research, with the goal of accelerating the delivery of new therapies to patients. As part of the Oncology Site Network, VHIO will have the opportunity to participate in an increased volume of clinical trials, with a dedicated relationship manager supporting the site and facilitating optimal matching to protocols.
“We are delighted to be selected as a to participate in this important program. Pooling experience, harnessing and exchanging insights with other best-in-class sites in the Catalyst Network, will advance best practices, predictive team science, and clinical study design,” noted Elena Garralda, Principal Investigator of VHIO’s Early Clinical Drug Development Group, and Director of its Research Unit for Molecular Therapy of Cancer (UITM) –”la Caixa”.
“Our Catalyst Site program demonstrates that when we collaborate with leading sites like VHIO and partners, it’s possible to accelerate start up and run trials more predictably,” said Clare Grace, PhD, Vice President, Site and Patient Access, Syneos Health. “To date, the trials run through our Oncology Site Network have 71% higher enrollment compared with non-Catalyst sites participating in the same studies. In the oncology space, where every day counts, streamlining development can realize powerful benefits for patients.”
